With clinical news pouring from pharma giants matching up the indoleamine 2,3-dioxygenase 1 (IDO1) blocker mechanism with PD-1 immune checkpoint inhibitors, Newlink Genetics Corp.'s interim results from NLG2103 – a phase II study evaluating its IDO pathway blocker indoximod as a combo candidate in advanced melanoma – seemed to take a back seat.